Free CME: Addressing the challenges of HPV vaccination
Wednesday, January 4, 2017
Posted by: Kia LaBracke
HPV is a common virus, with nearly 1 in 4 people (~80 million people) in the U.S. who are currently infected, and an estimated 14 million who are newly infected each year. HPV causes cervical, vaginal, vulvar, anal, oropharynx and penile cancers as well as genital warts.1 As the only cancer-prevention vaccines licensed by the FDA, HPV immunization offers significant opportunities to diminish important and potentially deadly cancers. Despite these advantages, HPV vaccination rates lag behind those for other vaccines in these age groups, such as tetanus, diphtheria and pertussis (Tdap). Studies suggest that 40% of adolescent females and 60% of adolescent boys have not started any course of HPV vaccination.2
This program will address the barriers to HPV vaccination in females and males and provide key rationales for why these immunizations are important to receive so that healthcare providers provide effective communication. Additionally, frequent questions regarding previous or incomplete HPV vaccine administration will be addressed. Special focus will be made on proven strategies that support HPV vaccination uptake regardless of clinical setting.
More information here.
- Paul G. Auwaerter, MD, MBA, FIDSA
- David Bell, MD, MPH
- Lawrence Herman, MPA, PA-C, DFAAPA
Physicians – maximum of 1.0 AMA PRA Category 1 Credit™
Presented by The Johns Hopkins University School of Medicine.
Supported by an independent educational grant from Merck.